Ocuphire Pharma, Inc.

[Available On-Demand]
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free formulation of phentolamine mesylate designed to reduce pupil size. Nyxol is being developed for treatment of night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME.
Ticker:
OCUP
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Michigan
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Nyxol® Eye Drops
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2 for non-U.S. rights
Speaker
photo
CEO
Ocuphire Pharma Inc